Post-infectious disorder
MONDO:0021669A disorder that follows infection but is distinct from the infection itself and its usual manifestations.
Also known as: sequela of infectious disorder
1770 clinical trials for this condition and its sub-types, 2 tagged with Post-infectious disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Post-infectious disorder
-
Post-viral disorder 5 trials · 1,707 incl. sub-types
13 sub-types
- Virus associated tumor 5 trials · 1,241 incl. sub-types Sub-types →
- Post-COVID-19 disorder 107 trials · 302 incl. sub-types Sub-types →
- Herpes zoster 73 trials Sub-types →
- Hepatitis D virus infection 47 trials
- Post-infectious neuralgia 0 trials · 33 incl. sub-types Sub-types →
- AIDS-related disorder 3 trials · 14 incl. sub-types Sub-types →
- Immunodeficiency 32B 9 trials
- AIDS dementia complex 6 trials
- Hepatitis C induced liver cirrhosis 5 trials
- Zika virus congenital syndrome 1 trial
- Oral hairy leukoplakia 0 trials
- Rubella encephalitis 0 trials Sub-types →
- Viral dilated cardiomyopathy 0 trials
-
Post-bacterial disorder 0 trials · 30 incl. sub-types
2 sub-types
- Rheumatic fever 16 trials
- Post-treatment Lyme disease syndrome 15 trials
-
Postinfectious encephalitis 0 trials · 13 incl. sub-types
7 sub-types
- Acute disseminated encephalomyelitis 7 trials · 8 incl. sub-types Sub-types →
- Limbic encephalitis with LGI1 antibodies 3 trials
- Rasmussen subacute encephalitis 2 trials
- Bickerstaff brainstem encephalitis 0 trials
- Encephalitis lethargica 0 trials
- Rubella encephalitis 0 trials Sub-types →
- Steroid-responsive encephalopathy associated with autoimmune thyroiditis 0 trials
-
Otitis externa 3 trials · 12 incl. sub-types
4 sub-types
- Malignant otitis externa 5 trials Sub-types →
- Otomycosis 4 trials Sub-types →
- Acute otitis externa 0 trials Sub-types →
- Perichondritis of auricle 0 trials Sub-types →
-
Post-infectious syndrome 5 trials · 10 incl. sub-types
3 sub-types
- KSHV inflammatory cytokine syndrome 4 trials
- Zika virus congenital syndrome 1 trial
- TORCH syndrome 0 trials
-
Chagas cardiomyopathy 3 trials
-
Encephalopathy, acute, infection-induced 2 trials · 3 incl. sub-types
1 sub-type
-
Infectious neuropathy 2 trials
-
Infection-related hemolytic uremic syndrome 0 trials · 2 incl. sub-types
2 sub-types
-
Infected hydrocele 0 trials
-
Infectious otitis interna 0 trials
-
Infective urethral stricture 0 trials
-
Postinfectious vasculitis 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 712 trials in this tab.
-
Patient's own t cells engineered to hunt lymphoma in early trial
Cure Recruiting nowResearchers are testing a personalized cell therapy called MT-601 in adults with Hodgkin or non-Hodgkin lymphoma that has come back or stopped responding to treatment. MT-601 is made from each participant's own T cells, which are trained in the lab to recognize several targets fo…
Phase 1 • Sponsor: Marker Therapeutics, Inc. • Aim: Cure
Last updated Sep 17, 2026 00:00 UTC
-
Can a powerful combo of drugs and stem cell transplant beat tough lymphomas in kids?
Cure Recruiting nowThis trial is testing a two-step approach for children, teens, and young adults with advanced T-cell or NK-cell lymphoma or leukemia. First, patients receive a combination of chemotherapy and immunotherapy drugs to shrink the cancer. Then, those who respond go on to receive a ste…
Early phase 1 • Sponsor: New York Medical College • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThis early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Cure Recruiting nowThis trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…
Phase 1 • Sponsor: Stanford University • Aim: Cure
Last updated Aug 14, 2026 00:00 UTC
-
Can targeted drugs blinatumomab and venetoclax improve outcomes for childhood leukemia?
Cure Recruiting nowThis large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…
Phase 2/3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Jul 25, 2026 00:00 UTC
-
Robotic surgery may spare throat cancer patients from chemo and radiation
Cure Recruiting nowThis phase 2 trial is testing whether robotic surgery alone can control HPV-related throat cancer, potentially sparing patients the long-term side effects of chemotherapy and radiation. The study enrolls people with HPV-positive oropharyngeal cancer whose tumors are removable and…
Phase 2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Cure
Last updated Jul 24, 2026 00:00 UTC
-
MRNA shot takes aim at the nerve pain of shingles
Vaccine Recruiting nowResearchers are testing an experimental mRNA vaccine called ABO1108 to see whether it can prevent herpes zoster, the painful rash also known as shingles. The trial enrolls adults aged 40 and older, including people whose long-term conditions are stable. Participants receive two i…
Phase 3 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Sep 16, 2026 00:00 UTC
-
New vaccine aims to block HPV cancers missed by current shots
Vaccine Recruiting nowThis early-stage trial tests a new vaccine called RG1-VLP in 18 healthy women aged 18-60. The vaccine targets HPV types not covered by existing vaccines like Gardasil 9. Researchers will check if it is safe and triggers a strong immune response. If it works, it could help prevent…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Vaccine
Last updated Sep 11, 2026 00:00 UTC
-
Blood cancer patients needed for flu vaccine showdown
Vaccine Recruiting nowThis study compares three different flu vaccines in 60 adults with blood cancers like leukemia or lymphoma. The goal is to see which vaccine triggers the strongest immune response in people with weakened immune systems. Participants will receive one of the vaccines and have their…
Phase 3 • Sponsor: Asan Medical Center • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
-
Can the shingles vaccine protect transplant patients? new study aims to find out
Vaccine Recruiting nowThis study tests the shingles vaccine (SHINGRIX) in 160 people: transplant recipients on different immunosuppressant drugs and their healthy housemates. Researchers will measure immune responses at five time points over a year to see if the vaccine works well in these groups. The…
Sponsor: Central Adelaide Local Health Network Incorporated • Aim: Vaccine
Last updated Jun 27, 2026 12:05 UTC
-
Can a shingles shot protect transplant patients? timing may be key.
Vaccine Recruiting nowThis study looks at how well the shingles vaccine Shingrix works in people who have had a stem cell transplant. About 55 adults who received the vaccine at least a year after their transplant will have their immune responses measured. Researchers want to see if the timing of the …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Vaccine
Last updated Jun 27, 2026 09:02 UTC
-
Boosting transplants with donor immune cells to fight blood cancer relapse
Disease control Recruiting nowThis study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to boost survival in hodgkin lymphoma
Disease control Recruiting nowThis phase 3 trial is testing whether adding immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy (with or without radiation) improves survival for people aged 5 to 60 with newly diagnosed stage I or II classical Hodgkin lymphoma. About 1,875 participa…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail aims to tame tough lymphoma
Disease control Recruiting nowThis study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink tumors or stop the cancer from growing. About 36 adults who have already tried o…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody AU-007 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…
Phase 1/2 • Sponsor: Aulos Bioscience, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Promising new combo aims to beat aggressive leukemia
Disease control Recruiting nowThis phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for tough leukemia: MK-1045 takes on standard therapy
Disease control Recruiting nowThis study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…
Phase 2/3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Personalized chemo boosts CAR T-Cell success in young leukemia patients
Disease control Recruiting nowThis study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug trial hopes to shrink tumors in kids with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a drug called zilovertamab vedotin in children and young adults whose blood cancers (like certain leukemias and lymphomas) or solid tumors (neuroblastoma, Ewing sarcoma) have come back or not responded to treatment. The goal is to see if the drug is safe and can …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could immunotherapy replace chemo in nasopharyngeal cancer?
Disease control Recruiting nowThis phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New 5-Drug combo aims to tackle tough lymphoma
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take on childhood blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new CAR T-cell therapy called AUTO1 (obe-cel) in up to 30 children with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The therapy uses the child's own immune cells, which are…
Phase 1 • Sponsor: Autolus Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug BL-M14D1 targets tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delive…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Promising new combo therapy for infant leukemia shows potential
Disease control Recruiting nowThis study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a probiotic fight anal cancer in HIV patients?
Disease control Recruiting nowThis study tests whether a probiotic called EXE-346 can help treat anal high-grade squamous intraepithelial lesions (HSIL) and reduce persistent high-risk HPV infection in people living with HIV. The trial will enroll 90 participants who will take the probiotic or a placebo daily…
Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New combo therapy aims to stop brain cancer growth in older patients
Disease control Recruiting nowThis study tests whether adding the drug ibrutinib to standard chemotherapy can better control primary central nervous system lymphoma (PCNSL) in people who are not eligible for a stem cell transplant. About 30 adults aged 65 or older or with other health issues will receive the …
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Second-Chance CAR-T: could Off-Spec cells still fight cancer?
Disease control Recruiting nowThis phase 3 trial is testing a CAR-T cell therapy called tisagenlecleucel that didn't quite meet commercial release standards. It's for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma who have no other approved options. The study will check if th…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Blood test may let some throat cancer patients skip radiation after surgery
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immune cell therapy aims to stop blood cancer relapse after transplant
Disease control Recruiting nowThis early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…
Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a new drug called AZD3470, alone or with pembrolizumab (Keytruda), in people with certain blood cancers like lymphoma. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 161 adults and teens will take part.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New CAR-T therapy aims to save kids with Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, called UCD19 CAR-T, in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) or B-cell non-Hodgkin lymphoma (B-NHL) that has come back or not responded to standard treatment. The therapy is made locally to sp…
Phase 1/2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could a lower dose of a transplant drug be better for blood cancer patients?
Disease control Recruiting nowThis study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Could chemo before surgery beat sarcoma? new trial aims to find out
Disease control Recruiting nowThis study is for people with a rare, high-risk cancer called retroperitoneal sarcoma. It compares two approaches: getting chemotherapy before surgery versus surgery alone. The goal is to see if the chemo-first approach helps prevent the cancer from coming back. About 250 partici…
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for hepatitis delta: can switching drugs clear the virus?
Disease control Recruiting nowThis study tests whether switching from the current drug bulevirtide to a new drug called brelovitug can better control chronic hepatitis Delta. About 120 adults who have been on bulevirtide for at least 6 months will take brelovitug for 24 weeks. The main goal is to see if the v…
Phase 2/3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental combo aims to tackle tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Blood test may guide safer chemo for hodgkin lymphoma patients
Disease control Recruiting nowThis phase 2 trial is testing whether a blood test that measures tumor DNA (ctDNA) can help doctors safely reduce the amount of chemotherapy for people with advanced Hodgkin lymphoma. After two cycles of standard chemo, patients with undetectable ctDNA may receive fewer total cyc…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for cancer survivors: drug aims to shield against Life-Threatening infections
Disease control Recruiting nowThis study tests a drug called IgPro20 in 63 adults who have a weakened immune system after receiving CAR T-cell therapy for blood cancers like lymphoma or multiple myeloma. The goal is to see if the drug can lower the number of serious bacterial infections, such as pneumonia or …
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New radioactive drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, 225Ac-ETN029, in 116 adults with advanced DLL3-positive cancers like small cell lung cancer or neuroendocrine tumors. The main goal is to check safety and find the right dose, while also seeing if the drug can shrink tumors. Pa…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare blood cancer: drug combo targets hard-to-treat lymphoma
Disease control Recruiting nowThis study tests whether adding daratumumab to standard drugs (bortezomib and dexamethasone) can shrink tumors in people with a rare and aggressive blood cancer called plasmablastic lymphoma that has returned or not responded to prior therapy. About 28 adults will receive the com…
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Supercharged cord blood cells take on resistant blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of immune cell therapy for people with several kinds of blood cancers that have come back or stopped responding to treatment. The therapy uses natural killer (NK) cells from donated cord blood, which are genetically modified to better recog…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New study targets rare Virus-Driven inflammatory syndrome
Disease control Recruiting nowThis study looks at a newly recognized disease called KSHV Inflammatory Cytokine Syndrome (KICS), caused by a virus that can also lead to certain cancers. Researchers aim to learn more about the disease and test experimental treatments, including antiviral and chemotherapy drugs,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas and leukemias
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T cell therapy called Azer-cel, which is made from healthy donor cells rather than the patient's own cells. It aims to treat adults with relapsed or refractory non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and relat…
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4152199 in about 215 adults with certain types of blood cancer (like follicular lymphoma or diffuse large B-cell lymphoma) that have already been treated. The drug is designed to help the body's immune cells attack the cancer. The …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a drug duo outsmart Treatment-Resistant hodgkin lymphoma?
Disease control Recruiting nowThis trial tests whether combining brentuximab vedotin and nivolumab can shrink tumors in people with classic Hodgkin lymphoma that has come back or resisted prior treatments. Participants must have already tried brentuximab or checkpoint inhibitors. The drugs work differently: b…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Lab-Grown immune cells take on dangerous viruses in vulnerable patients
Disease control Recruiting nowThis study tests whether specially grown donor immune cells (called cytotoxic T lymphocytes) can safely and effectively control BK and JC virus infections in people with weakened immune systems, such as those with cancer, HIV, or organ transplants. About 100 participants will rec…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New surgery aims to cut pancreatic leak and diabetes risk
Disease control Recruiting nowThis study tests a surgery called total pancreatectomy with islet autotransplantation (TPIAT) in 30 adults with certain pancreatic tumors who are at high risk for a dangerous leak after standard surgery. The procedure removes the entire pancreas and transplants the insulin-making…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New oral drug takes on tough brain cancer in phase 3 trial
Disease control Recruiting nowThis phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…
Phase 3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for young cancer patients: glofitamab trial targets tough lymphoma
Disease control Recruiting nowThis study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy aims to beat leukemia in young adults
Disease control Recruiting nowThis phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo injection targets Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Engineered immune cells take on brain cancer in pioneering trial
Disease control Recruiting nowThis study is testing a new type of immunotherapy called liso-cel (Breyanzi) as the first treatment for primary central nervous system lymphoma (PCNSL), a rare brain cancer. The trial is for 65 adults who cannot have a stem cell transplant. Liso-cel is made from the patient's own…
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Experimental antibody takes aim at Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy aims to outsmart relapsed leukemia in kids
Disease control Recruiting nowThis phase 2 trial is testing whether adding nivolumab to blinatumomab helps children and young adults (ages 1 to 30) with relapsed B-cell acute lymphoblastic leukemia (B-ALL), including those with Down syndrome. Blinatumomab helps the immune system find and kill cancer cells, wh…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Promising new combo aims to tame hodgkin lymphoma in young patients
Disease control Recruiting nowThis study tests whether adding nivolumab to standard chemotherapy (AVD) can better control early-stage Hodgkin lymphoma in patients aged 2 to 21. The treatment is given to 15 participants to see if it is safe and effective. The goal is to improve outcomes while reducing long-ter…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for kidney transplant patients with advanced skin cancer
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug mosunetuzumab takes on rituximab in rare lymphoma trial
Disease control Recruiting nowThis phase 2 trial tests whether mosunetuzumab, a newer antibody, works better than the standard rituximab for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). About 70 patients with untreated or previously treated NLPHL will receive one of the two drugs. The main goal is…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to outdo chemo for tough throat cancer
Disease control Recruiting nowThis Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of thr…
Phase 3 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Could delaying radiation be just as good for advanced nasopharyngeal cancer?
Disease control Recruiting nowThis phase 3 trial is testing whether giving radiation only when needed (salvage therapy) works as well as giving it right away after immunotherapy and chemotherapy in people with nasopharyngeal cancer that has spread. The goal is to see if delaying radiation can reduce side effe…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can less radiation be just as good for hodgkin lymphoma?
Disease control Recruiting nowThis phase 3 trial is testing whether a lower dose of radiation (20 Gy) is as effective as the standard dose (30 Gy) for people with early-stage, unfavorable Hodgkin lymphoma. Only patients whose cancer shows a complete metabolic response after two cycles of chemotherapy will be …
Phase 3 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for rare cancer: ivonescimab trial targets leiomyosarcoma
Disease control Recruiting nowThis study tests whether the drug Ivonescimab can safely shrink or control advanced leiomyosarcoma, a rare soft-tissue cancer. About 20 adults who have already tried 1-3 prior treatments will receive the drug. The goal is to see if it slows tumor growth with few side effects.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New hope for rare liver disease: experimental drug GS-4321 enters human trials
Disease control Recruiting nowThis study tests a new drug called GS-4321 for chronic hepatitis delta, a serious liver infection. First, healthy volunteers will help determine safe dosing. Then, people with the disease will receive multiple doses to see if the drug can reduce virus levels and improve liver hea…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New CAR-T therapy aims to tackle tough blood cancers
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and attack cancer cells. The main goa…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could a breast cancer drug tame kaposi sarcoma?
Disease control Recruiting nowThis study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS), both with and without HIV. The goal is to find a safe dose and see if it can shrink KS tumors. About 111 adults will take the drug daily in 28-day cycles until their ca…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Could a Lab-Made protein help fight HIV-Related cancer?
Disease control Recruiting nowThis study tests a lab-made human protein called CYT107 in 55 people with HIV and Kaposi sarcoma. The protein aims to boost T cells, which may help shrink cancer tumors. Participants receive weekly injections for up to 4 weeks, with follow-up for 3 years.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo aims to beat tough childhood leukemia
Disease control Recruiting nowThis phase 3 trial tests whether adding the targeted drug inotuzumab ozogamicin to standard chemotherapy and immunotherapy improves outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The study will enroll about 6,000 participants an…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope: drug combo targets HIV-Linked cancers
Disease control Recruiting nowThis early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for hepatitis delta: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial compares a new drug, brelovitug, to an existing treatment (bulevirtide) for chronic hepatitis delta, a serious liver infection. About 172 adults with the infection will receive either drug to see which better controls the virus and normalizes liver enzymes. The…
Phase 3 • Sponsor: Mirum Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
Disease control Recruiting nowThis study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …
Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…
Phase 1/2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for rare cancers: daratumumab trial targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis phase 2 trial tests the drug daratumumab in 28 adults with three rare and aggressive blood cancers: primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease. Participants must have failed standard therapy or be unable to receive it. Daratumumab i…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug trial targets deadly inflammation in HIV patients
Disease control Recruiting nowThis study tests a drug called pacritinib in people with HIV who have two rare conditions caused by the Kaposi sarcoma herpesvirus (KSHV): KSHV-associated multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). These conditions cause severe, life-thre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Two-Drug attack shrink recurrent throat cancer?
Disease control Recruiting nowThis phase II trial is testing whether combining becotatug vedotin with a PD-1 inhibitor can help people with recurrent nasopharyngeal carcinoma (a type of throat cancer). Participants will receive the drug combination for three cycles, then be evaluated for surgery. The goal is …
Phase 2 • Sponsor: Hongmeng Yu • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for hepatitis d: libevitug enters final testing phase
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study comp…
Phase 3 • Sponsor: Huahui Health • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo aims to outsmart kaposi sarcoma tumors
Disease control Recruiting nowThis study tests two drugs, PDS01ADC and M7824, that work with the immune system to fight Kaposi sarcoma (KS), a cancer often linked to HIV or organ transplants. The trial enrolls 80 adults with advanced KS that has not responded well to prior therapy. Participants receive PDS01A…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Fighting fat to fight leukemia: could a diet and exercise plan boost chemo?
Disease control Recruiting nowThis trial tests whether a personalized diet and exercise plan during the first month of chemotherapy can make leukemia cells more sensitive to treatment in older children, adolescents, and young adults with B-cell acute lymphoblastic leukemia (B-ALL). The study also aims to redu…
Phase 2 • Sponsor: Etan Orgel • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Tailored radiation aims to shrink tumors, spare healthy tissue in nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether a personalized radiation plan, which expands the treatment area based on each patient's tumor margins, can control nasopharyngeal cancer as well as the standard approach. The study includes 568 adults with newly diagnosed, non-metastatic disease. …
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for tough leukemia: experimental drug AZD0486 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called AZD0486 in adolescents and adults whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or not responded to at least two prior treatments. The trial has three parts: first, finding a safe dose; second, optimizing that dose; an…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for hodgkin lymphoma patients unable to tolerate chemo
Disease control Recruiting nowThis study tests a drug called tislelizumab in people with newly diagnosed Hodgkin lymphoma who are not able to receive standard chemotherapy. The goal is to see if the drug can shrink or control the cancer. About 28 participants will take part in this phase 2 trial.
Phase 2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Blood test could guide anal cancer treatment, reducing side effects
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an adde…
Phase 2 • Sponsor: Jennifer Dorth • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a blood test and MRI tailor cancer therapy to each patient?
Disease control Recruiting nowThis trial tests whether giving extra chemotherapy or a combination of chemotherapy and immunotherapy after standard treatment can improve outcomes for people with nasopharyngeal carcinoma. The choice of treatment is based on each patient's risk level, determined by changes in a …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immunotherapy combo may outperform chemo in rare lymphoma
Disease control Recruiting nowThis Phase 3 trial tests whether an immunotherapy-based regimen (sintilimab, pegaspargase, and anlotinib) works better than standard chemotherapy before a stem cell transplant in people with newly diagnosed, advanced extranodal NK/T-cell lymphoma. Participants are randomly assign…
Phase 3 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug KUP-101A enters first human tests for advanced skin cancers
Disease control Recruiting nowThis early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…
Phase 1 • Sponsor: Kupando GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
Disease control Recruiting nowThis phase 3 trial is testing whether an investigational drug called INT230-6, which combines three anti-cancer agents and is injected directly into tumors, can help people with advanced soft tissue sarcoma live longer than those receiving standard care. The study enrolls adults …
Phase 3 • Sponsor: Intensity Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo after brain radiation shows promise for lymphoma patients
Disease control Recruiting nowThis early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…
Phase 1 • Sponsor: University of Utah • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug karonudib tested in blood cancer patients
Disease control Recruiting nowThis early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…
Phase 1 • Sponsor: Thomas Helleday Foundation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Four-Pronged attack beat brain lymphoma?
Disease control Recruiting nowThis trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …
Phase 2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Phase 1/2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
Disease control Recruiting nowThis phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…
Phase 2 • Sponsor: Lakshmi Nayak, MD • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
Disease control Recruiting nowThis trial tests whether a blood test that detects HPV DNA can help doctors personalize treatment for people with HPV-related throat cancer. Participants receive radiation therapy, with or without chemotherapy, but the intensity is adjusted based on their blood test results and c…
Phase 2 • Sponsor: Jonathan Schoenfeld, MD, MPH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a daily pill keep brain lymphoma at bay after remission?
Disease control Recruiting nowThis trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…
Phase 2 • Sponsor: Kyorin University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a smart brain implant outsmart chronic pain?
Disease control Recruiting nowThis trial tests whether a new type of deep brain stimulation (DBS) can better relieve chronic pain that hasn't responded to other treatments. Unlike traditional DBS, which delivers constant stimulation, this approach uses a device that adapts stimulation in real time based on br…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug takes aim at Hard-to-Treat sarcoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called REC-617 in 15 people with a rare type of sarcoma (leiomyosarcoma) that has spread or cannot be removed and has not responded to prior treatments. The drug targets a protein (CDK7) that helps cancer cells grow. The main goal is t…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail shows promise for Tough-to-Treat throat cancer
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people with recurrent or metastatic nasopharyngeal cancer that hasn't been treated before. About 100 participants will receive the combination int…
Phase 4 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can Long-Acting HIV shots outperform daily pills during lymphoma treatment?
Disease control Recruiting nowThis trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …
Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
Disease control Recruiting nowThis study is for people with HPV-related throat cancer. After surgery, patients receive lower-than-standard doses of radiation and sometimes chemotherapy, based on their risk level. The goal is to keep cancer from coming back while reducing side effects like weight loss. About 1…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Phase 3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Supercharged donor cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost th…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Experimental combo therapy targets multiple cancers in new trial
Disease control Recruiting nowThis study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…
Phase 1/2 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
Disease control Recruiting nowThis phase III trial tests whether a shorter, 'immune sandwich' regimen works as well as full-course immunotherapy for locally advanced nasopharyngeal carcinoma. The experimental group gets induction chemotherapy plus two immune-targeting drugs (toripalimab and nimotuzumab), then…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug duo aims to keep advanced nasopharyngeal cancer in check
Disease control Recruiting nowThis Phase III trial tests whether adding an experimental drug called becotatug vedotin to standard anti-PD1 immunotherapy can better control advanced nasopharyngeal carcinoma that has spread or returned. About 86 adults whose cancer has stabilized after initial chemoimmunotherap…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New antibody combo aims to treat brain lymphoma
Disease control Recruiting nowThis trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…
Phase 1/2 • Sponsor: James Rubenstein • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Double-Targeting antibody takes on Hard-to-Treat throat cancer
Disease control Recruiting nowThis trial tests a new drug called JS207, a bispecific antibody that targets two proteins (PD1 and VEGF) involved in cancer growth and immune evasion. It is being studied in people with recurrent or metastatic nasopharyngeal carcinoma, a type of throat cancer, who have already tr…
Phase 2 • Sponsor: Chinese University of Hong Kong • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowThis phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New antibody drug takes aim at relapsed leukemia
Disease control Recruiting nowThis study tests a new drug called AZD4512 for people with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. The drug is an antibody-drug conjugate that delivers a toxic payload directly to cancer cells. The trial has two parts: first, f…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Vaccine trains immune system to fight HPV-Positive head and neck tumors
Disease control Recruiting nowThis trial tests a vaccine called BVAC-E6E7 in people with head and neck cancer linked to HPV types 16 or 18 that cannot be removed by surgery or has spread. The vaccine is designed to teach the immune system to attack cancer cells. The study first checks safety and the best dose…
Phase 1/2 • Sponsor: Cellid Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
PET-Guided chemotherapy trial aims to improve hodgkin lymphoma treatment
Disease control Recruiting nowThis phase 3 trial compares two chemotherapy combinations (ABVD and A2VD) for people with newly diagnosed, early-stage Hodgkin lymphoma. About 1,042 participants will receive 3-4 cycles of chemo, with a PET scan after 2 cycles to tailor further treatment. The goal is to see which…
Phase 3 • Sponsor: University College, London • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Heart device showdown: could CCM beat CRT for chagas patients?
Disease control Recruiting nowThis study compares two implantable heart devices—Cardiac Contractility Modulation (CCM) and Cardiac Resynchronization Therapy (CRT)—in people with Chagas heart disease and advanced heart failure. The goal is to see which device better improves quality of life and heart function.…
Sponsor: InCor Heart Institute • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo attack on liver metastases from nasopharyngeal cancer enters human trials
Disease control Recruiting nowThis phase 2 trial tests whether adding low-dose radiation to standard chemoimmunotherapy can better control liver tumors in people with nasopharyngeal carcinoma that has spread to the liver. The study will enroll 26 adults aged 18 to 70. Participants will receive low-dose radiat…
Phase 2 • Sponsor: Hunan Cancer Hospital • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New transplant recipe aims to tame Graft-Versus-Host disease
Disease control Recruiting nowThis study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Immune booster may strengthen stem cell transplant against hodgkin lymphoma
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to a standard stem cell transplant can help people with Hodgkin lymphoma that has come back or not responded to treatment. Participants receive pembrolizumab before and after their own stem cells are …
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-phase trial tests a new type of immune cell therapy for patients with EBV-positive Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard treatments. The researchers add a gene called C7R to the patient's own T cells to help them survive longer …
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New CAR-T therapy aims to keep High-Risk leukemia in remission
Disease control Recruiting nowThis study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…
Phase 2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether combining pembrolizumab (Keytruda) with bendamustine (Treanda) is safe and effective for people with Hodgkin lymphoma that has come back or is no longer responding to standard treatments. About 40 adults will receive the drug combination, and rese…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Home-Based program aims to help long COVID patients breathe easier and move more
Disease control Recruiting nowThis study tests a comprehensive, remotely delivered care program for people aged 40 and older with Long COVID who have ongoing heart or lung symptoms like fatigue, shortness of breath, or chest pain. The program includes medication review, mental health support, telehealth coach…
Sponsor: University of Tasmania • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope: drug before surgery may stop merkel cell cancer spread
Disease control Recruiting nowThis study tests whether giving the drug cemiplimab before lymph node surgery can prevent Merkel cell carcinoma from spreading to nearby lymph nodes. About 135 adults with early-stage cancer will receive either the drug or a placebo before their scheduled biopsy. The goal is to s…
Phase 2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo attack on rare blood cancer shows promise in early trial
Disease control Recruiting nowThis study tests two drugs, tislelizumab and zeprumetostat, together in people with a rare type of lymphoma that has come back or not responded to treatment. About 107 adults will take part to see if the combination is safe and shrinks tumors. The goal is to control the cancer, n…
Phase 1/2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New CAR-T therapy aims to keep leukemia in remission
Disease control Recruiting nowThis study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…
Phase 1/2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Alpha radiation seeds target tumors from the inside
Disease control Recruiting nowThis study tests a device called DaRT that delivers a unique type of radiation (alpha particles) directly into tumors. It is designed for people with certain skin cancers, mouth cancers, or soft tissue sarcomas that are accessible for direct injection. The goal is to see if this …
Sponsor: Alpha Tau Medical LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AB821 enters first human tests for advanced melanoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
Phase 1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat brain cancer: combo therapy enters trial
Disease control Recruiting nowThis study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer. About 60 adults…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer-Killing virus shows promise in early trial for advanced tumors
Disease control Recruiting nowThis early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…
Phase 1 • Sponsor: Memgen, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo aims to outsmart Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…
Phase 1 • Sponsor: Epkin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Engineered t cells take on lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets rare, aggressive cancer
Disease control Recruiting nowThis phase 2 trial is testing whether combining two chemotherapy drugs—Abraxane and liposomal doxorubicin—can shrink tumors in people with advanced or unresectable angiosarcoma, a rare and aggressive cancer of blood vessels. The study will enroll 69 patients who have already trie…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could less radiation be enough for some lymphoma patients?
Disease control Recruiting nowThis study looks at whether a lower dose of radiation can safely prevent cancer from returning in people with early-stage nasal-type NK/T-cell lymphoma who have already had a complete response to chemotherapy. Participants receive 45 Gy of radiation over five weeks, targeting the…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for tough lymphomas: balstilimab trial opens
Disease control Recruiting nowThis study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…
Phase 2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New risk model may let some NPC patients avoid unnecessary chemo
Disease control Recruiting nowThis study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to …
Phase 3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for Hard-to-Treat brain cancer: targeted radiation trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. About 15 participants will receive one intrave…
Phase 1/2 • Sponsor: Pentixapharm AG • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy aims to beat childhood lymphoma
Disease control Recruiting nowThis study is testing whether adding the drug rituximab early and intensively to a strong chemotherapy regimen can improve outcomes for children and teens with aggressive B-cell non-Hodgkin lymphoma. About 87 participants will receive the combination therapy. The goal is to see i…
Phase 2/3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New transplant method aims to cut dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New formula aims to help long COVID sufferers walk farther
Disease control Recruiting nowThis study tests a new supplement called PNMR in 82 adults with long COVID. Participants either take PNMR plus standard care or standard care alone for 6 weeks. The main goal is to see if PNMR helps people walk farther in a 6-minute test. All participants also get diet and lifest…
Phase 2 • Sponsor: ParagonClinicals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cocktail of drugs takes on rare brain cancer
Disease control Recruiting nowThis phase 2 trial tests a combination of four drugs—pirtobrutinib, sintilimab, rituximab, and high-dose methotrexate—as a first treatment for adults with newly diagnosed primary central nervous system lymphoma (PCNSL). About 77 participants will choose either this experimental c…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Diet and exercise may ease long COVID symptoms in obese veterans
Disease control Recruiting nowThis study looks at how obesity affects recovery from post-COVID conditions in older Veterans. Researchers will test if a weight loss program with diet and exercise can reduce inflammation and improve physical function and quality of life. The study involves 150 Veterans, some wi…
Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a common cholesterol drug slow liver scarring?
Disease control Recruiting nowThis study tests whether rosuvastatin, a cholesterol-lowering drug, can safely slow or stop liver scarring (cirrhosis) compared to a placebo. About 256 adults with compensated cirrhosis will take the drug or placebo for 2 years. The main goal is to measure changes in liver stiffn…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can a two-drug combo beat the HTLV-1 virus?
Disease control Recruiting nowThis Phase 2 trial compares the drug dolutegravir alone versus dolutegravir combined with tenofovir in 146 adults with HTLV-1 infection and related symptoms. The main goal is to see if the combination lowers the virus level more effectively and improves pain, spasticity, and musc…
Phase 2 • Sponsor: Carlos Brites • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Brain cancer breakthrough? CAR t cells injected directly into fluid around brain in new trial
Disease control Recruiting nowThis early-phase trial tests a new approach to treat central nervous system (CNS) lymphoma by injecting specially engineered immune cells (CAR T cells) directly into the fluid surrounding the brain. The study involves 20 participants and aims to find the safest dose while monitor…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase 1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo tackles rare, aggressive lymphoma
Disease control Recruiting nowThis early study tests adding daratumumab, an antibody that targets a protein on cancer cells, to standard chemotherapy for people with newly diagnosed plasmablastic lymphoma, a rare and fast-growing cancer. The trial includes up to 15 participants, with or without HIV. The main …
Early phase 1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Phase 1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody could tame dual hepatitis b and d infection
Disease control Recruiting nowThis early-stage trial tests a lab-made antibody (HepB mAb19) in 15 people with chronic hepatitis D, a serious liver infection that requires hepatitis B to survive. The goal is to see if the antibody is safe and can lower virus levels, potentially reducing the risk of liver damag…
Phase 1 • Sponsor: Aarhus University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a targeted drug keep hodgkin lymphoma away after transplant?
Disease control Recruiting nowThis study is checking how well the drug brentuximab vedotin works for adults with Hodgkin lymphoma who have had a stem cell transplant. Researchers will track 70 participants for about 2 years to see if the drug helps prevent the cancer from coming back. It is an observational s…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
Disease control Recruiting nowThis study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…
Phase 1/2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Low-Dose radiation plus immunotherapy shows promise for Tough-to-Treat nasopharyngeal cancer
Disease control Recruiting nowThis Phase 2 trial is testing whether adding low-dose radiotherapy to a standard chemotherapy regimen (gemcitabine and cisplatin) plus the immunotherapy drug toripalimab can help control recurrent or metastatic nasopharyngeal carcinoma. About 55 adults aged 18-65 with confirmed n…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail aims to shrink brain tumors
Disease control Recruiting nowThis study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…
Phase 2 • Sponsor: Zou Dehui • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a Low-Dose immune drug ease long COVID symptoms?
Disease control Recruiting nowThis study tests whether a low dose of sirolimus (rapamycin), a drug that calms the immune system, can help adults with Long COVID feel better. Eighty participants will take either sirolimus or a placebo pill once a week for 12 weeks. The main goal is to see if the drug improves …
Phase 3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Heart shield for young cancer survivors: new study tests dexrazoxane
Disease control Recruiting nowThis study looks at whether a drug called dexrazoxane can help prevent heart damage in children and teens who have been treated for certain cancers like leukemia, lymphoma, and osteosarcoma. Researchers will measure heart function and blood markers in 420 survivors to see if dexr…
Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could less radiation be just as effective for HPV+ throat cancer?
Disease control Recruiting nowThis study is testing whether a lower dose of radiation (30 Gy) can safely treat HPV-positive oropharyngeal cancer while reducing side effects. About 31 adults with this type of throat cancer will receive the reduced radiation along with standard chemotherapy. The main goal is to…
Phase 2 • Sponsor: Sara Medek • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug combo aims to keep High-Risk nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed …
Phase 3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with tough cancers: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New stem cell transplant method aims to cut complications in young blood cancer patients
Disease control Recruiting nowThis pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…
Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New cocktail targets brain lymphoma: early trial launches
Disease control Recruiting nowThis early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adul…
Phase 1 • Sponsor: Juan P. Alderuccio, MD • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Double-Barreled attack: CAR-T plus stem cell transplant takes on aggressive lymphoma
Disease control Recruiting nowThis study tests a powerful two-step approach for people with a fast-growing type of lymphoma that has not responded to standard treatments. First, patients receive a CAR-T cell therapy (engineered immune cells) followed by a stem cell transplant with high-dose chemotherapy. The …
Phase 2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Cord blood transplant offers hope for young blood cancer patients
Disease control Recruiting nowThis study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Dual-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…
Phase 1 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a common numbing drug help fight throat cancer?
Disease control Recruiting nowThis early-stage trial is testing whether injecting the local anesthetic lidocaine into HPV-related throat tumors before robotic surgery is safe and might help destroy more cancer cells. About 30 adults with HPV-positive oropharyngeal cancer will receive the injection during a ro…
Phase 1 • Sponsor: Ryan Carey • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New triple therapy aims to control advanced nose cancer
Disease control Recruiting nowThis study tests a combination of three drugs—an EGFR antibody, a PD-1 inhibitor, and chemotherapy—in people whose nasopharyngeal cancer has returned or spread. The goal is to see if this mix can slow or stop the cancer from growing. About 148 adults aged 18-75 who have not had p…
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a rheumatoid arthritis drug ease long COVID brain fog?
Disease control Recruiting nowThis study tests whether baricitinib, a drug used for arthritis, can improve thinking, physical function, and quality of life in people with Long COVID. About 550 adults who had COVID-19 at least 6 months ago will receive either baricitinib or a placebo for 6 months. The main goa…
Phase 3 • Sponsor: Wes Ely • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough nasopharyngeal cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Partic…
Phase 2 • Sponsor: Ming-Yuan Chen • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can better nutrition improve outcomes for head and neck cancer patients?
Disease control Recruiting nowThis phase 3 trial tests whether a structured nutrition plan (including supplements, feeding tubes, or IV nutrition) helps malnourished patients with advanced nasopharyngeal carcinoma maintain weight and improve their prognosis. About 266 participants will receive either standard…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Nasal spray vaccine plus immunotherapy shows promise in early throat cancer trial
Disease control Recruiting nowThis early-phase trial is testing whether a nasal spray vaccine (WSK-IM05) combined with an immunotherapy drug (tislelizumab) can safely shrink HPV-positive throat tumors before surgery. Nine adults with newly diagnosed, resectable HPV-positive oropharyngeal cancer will receive t…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Radiation and immunotherapy combo shows promise for advanced nasopharyngeal cancer
Disease control Recruiting nowThis phase II trial is testing whether combining two types of radiation (SBRT and low-dose radiation) with an immunotherapy drug (toripalimab) and chemotherapy can help control recurrent or metastatic nasopharyngeal carcinoma. The study will enroll 148 participants who have not r…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could an immune booster beat long COVID? small trial begins
Disease control Recruiting nowThis Phase 2 trial tests the safety of a drug called Anktiva (N-803) in 20 adults with Long COVID. Participants get up to two shots and are monitored for side effects and changes in immune cells and quality of life. The goal is to see if the drug is safe enough to study further f…
Phase 2 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy combo aims to beat back recurrent nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug called toripalimab to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and who cannot have surgery will…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy boost may improve outcomes in returning throat cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemoradiotherapy helps people with recurrent nasopharyngeal carcinoma live longer. About 212 participants whose cancer has returned after prior treatment and cannot be surgically removed wi…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New surgery technique could improve survival in recurrent throat cancer
Disease control Recruiting nowThis study compares two surgical techniques for treating nasopharyngeal cancer that has come back after radiation. 500 participants will be randomly assigned to receive either low-temperature plasma ablation or high-frequency electrocautery. The goal is to see which method leads …
Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New trial aims to tame transplant complications in blood cancer patients
Disease control Recruiting nowThis phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could less radiation be enough for HPV throat cancer?
Disease control Recruiting nowThis study is testing whether a reduced dose of radiation can safely treat HPV-positive oropharyngeal (throat) cancer. About 111 patients will receive a lower total radiation dose than usual, with some also getting chemotherapy if needed. The goal is to see if this approach keeps…
Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New CAR-T therapy targets tough childhood cancers
Disease control Recruiting nowThis phase 2 trial is testing a new type of CAR-T cell therapy called MB-CART2019.1 in children and teens (ages 6 months to under 18) with B-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to atta…
Phase 2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy aims to beat leukemia without harsh chemo
Disease control Recruiting nowThis phase 2 trial is testing a new treatment strategy for adults newly diagnosed with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The approach combines a reduced-dose chemotherapy with a full course of the immunotherapy drug blinatumomab, and may a…
Phase 2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New immunotherapy combo aims to boost hodgkin lymphoma remission
Disease control Recruiting nowThis Phase 2 trial tests whether adding the immunotherapy drug penpulimab to standard AVD chemotherapy improves outcomes for people with newly diagnosed advanced classic Hodgkin lymphoma. About 108 adults will receive either concurrent or sequential treatment over several cycles.…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy aims to halt spread of nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding a precise form of radiation (SBRT) to the immunotherapy drug camrelizumab helps control cancer better than camrelizumab alone in people with nasopharyngeal cancer that has spread to a few spots (oligometastatic). About 188 adults whose prim…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…
Early phase 1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to stop brain lymphoma from returning
Disease control Recruiting nowThis phase 2 trial is testing whether a two-year maintenance treatment with lenalidomide and rituximab can prevent relapse in patients with primary central nervous system lymphoma who have responded to initial chemotherapy but are not eligible for a stem cell transplant. The stud…
Phase 2 • Sponsor: Kim, Seok Jin • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radioactive drug plus immunotherapy shows promise for rare skin cancer
Disease control Recruiting nowThis study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shri…
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo treatment may spare head and neck cancer patients from disfiguring surgery
Disease control Recruiting nowThis study tests giving chemotherapy and immunotherapy before standard surgery for head and neck cancer. The goal is to shrink tumors enough so that surgeons can perform less extensive, function-preserving operations, reducing damage to swallowing, speech, and vision. The trial e…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to tame advanced lymphomas in early trial
Disease control Recruiting nowThis early-phase study tests an experimental oral drug called AUR108 in adults with relapsed advanced lymphomas. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. About 40 participants will take the pill, and researchers will m…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could less radiation be enough for HPV throat cancer? new trial aims to find out.
Disease control Recruiting nowThis study is testing whether people with early-stage HPV-positive throat cancer can be treated with radiation alone at a lower dose, instead of the usual full-dose radiation plus chemotherapy. The goal is to see if this gentler approach can keep the cancer from coming back while…
Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Gene-Modified immune cells take on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called TranspoCART19 for people with B-cell lymphoma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells. The trial wi…
Phase 1/2 • Sponsor: Instituto de Investigación Biomédica de Salamanca • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Blood filtering shows promise for chronic fatigue sufferers
Disease control Recruiting nowThis study looks at a blood-filtering procedure called immunoadsorption (IA) in 50 people with ME/CFS or Post-COVID syndrome who have certain autoantibodies. The goal is to see if removing these antibodies improves symptoms like severe fatigue and brain fog. Researchers will trac…
Sponsor: Charite University, Berlin, Germany • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise for rare, aggressive blood cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug sintilimab to standard chemotherapy can help people with a rare and aggressive type of lymphoma (NK/T-cell lymphoma) that has spread. About 84 newly diagnosed patients will be randomly assigned to receive either the combinati…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase 1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells take on tough blood cancers in new trial
Disease control Recruiting nowThis study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…
Phase 2/3 • Sponsor: Health Institutes of Turkey • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for rare cancer: trabectedin vs gemcitabine in leiomyosarcoma trial
Disease control Recruiting nowThis phase II trial compares the chemotherapy drugs trabectedin and gemcitabine in 100 people with advanced leiomyosarcoma that has worsened after initial treatment. The study aims to see which drug better delays cancer progression. It also includes an observational group for tho…
Phase 2 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowThis early-stage trial tests a new type of CAR T-cell therapy (CMD63) in 16 children whose B-cell acute lymphoblastic leukemia has returned or not responded to standard treatments. The therapy uses specially engineered immune cells to target and kill cancer cells. The main goal i…
Phase 1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Can immunotherapy let doctors dial down cancer treatment without sacrificing cures?
Disease control Recruiting nowThis phase II trial is testing whether giving the immunotherapy drug cemiplimab (sometimes with chemotherapy) before standard treatment can shrink tumors enough to allow less intense local therapy, such as reduced radiation or surgery. The goal is to maintain high cure rates whil…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New immune cells take aim at Virus-Linked lymphomas
Disease control Recruiting nowThis study tests a new way to make immune cells (called GRALE T cells) that are trained to attack cells infected with the Epstein-Barr virus (EBV), which is linked to some lymphomas. The trial includes people with Hodgkin or non-Hodgkin lymphoma, or related diseases, whose cancer…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New study aims to boost survival for kids with Burkitt's lymphoma
Disease control Recruiting nowThis study involves 1,000 children with Burkitt's lymphoma, a fast-growing cancer. Researchers want to see if checking children earlier and adjusting treatment based on response can improve outcomes, especially for advanced-stage disease. The goal is to refine treatment recommend…
Sponsor: French Africa Pediatric Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Less radiation, same control? new trial aims to boost quality of life for throat cancer patients
Disease control Recruiting nowThis study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for rare sarcoma patients: AL3818 drug trial underway
Disease control Recruiting nowThis phase 3 trial tests the drug AL3818 (anlotinib) in people with advanced alveolar soft part sarcoma, leiomyosarcoma, or synovial sarcoma. Currently, only patients with alveolar soft part sarcoma are being enrolled. Participants receive AL3818 pills or a standard chemotherapy …
Phase 3 • Sponsor: Advenchen Laboratories, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could keytruda before surgery keep merkel cell cancer away?
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug pembrolizumab (Keytruda) can shrink Merkel cell carcinoma before surgery and lower the risk of it returning afterward. About 15 people with stage I to III Merkel cell carcinoma that can be surgically removed will receiv…
Phase 2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a cancer pill keep bone sarcomas at bay?
Disease control Recruiting nowThis study tests whether the drug regorafenib can help prevent bone sarcomas from coming back after initial treatment. About 168 people aged 12 and older with various bone sarcomas will be randomly assigned to take regorafenib for up to 12 months or to receive standard monitoring…
Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for bone sarcoma: regorafenib maintenance trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug regorafenib can help keep high-grade bone sarcomas from growing in patients who still have some disease after standard treatment. About 36 people aged 12 and older will take regorafenib daily for up to 12 months. The main goal is to see h…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for rare blood cancer: platform trial tests multiple drugs at once
Disease control Recruiting nowThis study is testing three oral drugs—roginolisib, golcadomide, and azacitidine—alone or in combination for people with peripheral T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: Phase 1 finds safe doses, and Phase 2 checks if the drug…
Phase 1/2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Tailored transplant doses aim to beat blood cancer
Disease control Recruiting nowThis phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…
Phase 2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Proton beam boost: new hope for inoperable sarcomas?
Disease control Recruiting nowThis study tests whether a higher dose of proton radiation can better control inoperable soft tissue sarcomas without increasing side effects. Forty adults with these rare tumors will receive targeted radiation over 4 weeks. Researchers will also look at blood and imaging markers…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New 3-Week radiation plan aims to cut side effects for sarcoma patients
Disease control Recruiting nowThis study tests whether a personalized 3-week course of proton radiation before surgery for soft tissue sarcoma can reduce long-term side effects compared to standard X-ray radiation. About 110 adults in Norway will receive either proton or X-ray therapy, chosen individually for…
Phase 2 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smart scans and DNA tests guide lymphoma treatment
Disease control Recruiting nowThis study tests a new way to treat a rare type of nasal lymphoma (NK/T cell lymphoma) by using PET scans and blood tests for the Epstein-Barr virus to decide the best treatment plan. About 89 newly diagnosed patients will receive a combination of chemotherapy, radiation, and imm…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Suicide-Gene t cells aim to stop blood cancer relapse
Disease control Recruiting nowThis early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…
Phase 1 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New pill aims to fight advanced lymphoma when other treatments fail
Disease control Recruiting nowThis early-stage trial tests an oral drug called AUR112 in 40 adults with relapsed advanced lymphoma. The main goals are to check safety, find the right dose, and see how the drug moves through the body. It is the first time this drug is being tested in humans.
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Can a drug calm long COVID's lung inflammation? new trial aims to find out
Disease control Recruiting nowThis study tests if the drug anakinra can help people with long COVID who have ongoing breathing issues and signs of an overactive immune system. About 182 adults will receive either anakinra or a placebo for up to 8 weeks. The goal is to see if the drug improves lung function, r…
Phase 2/3 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for sarcoma patients: immunotherapy plus chemo shows promise
Disease control Recruiting nowThis study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could blood filtering ease long COVID? new trial aims to find out
Disease control Recruiting nowSome people with long COVID have harmful antibodies that may be attacking their own bodies, causing severe fatigue and other symptoms. This study tests a treatment called immunoadsorption, which filters the blood to remove those antibodies. About 70 participants will receive eith…
Phase 2 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells take on virus-driven cancers in early trial
Disease control Recruiting nowThis study tests a new treatment called GP350 CAR-T cells for people with blood cancers that are linked to the Epstein-Barr virus and have not responded to standard therapy. The treatment involves collecting a patient's own immune cells, modifying them to better target the cancer…
Phase 1/2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New blood test could replace scans for HPV cancer patients
Disease control Recruiting nowThis study is testing a simple blood test that looks for tumor DNA from HPV-related cervical and anal cancers after radiation treatment. The goal is to see if this test can replace expensive imaging scans and help doctors find early signs of cancer returning. If the test is posit…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could less radiation be just as effective for neck cancer?
Disease control Recruiting nowThis study tests whether giving radiation only to the parts of the neck where cancer has spread works as well as treating the entire neck in people with nasopharyngeal carcinoma. About 462 adults with stage I–III disease will be randomly assigned to receive either standard or ind…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for recurrent throat cancer: Radiation-Immunotherapy combo shows promise
Disease control Recruiting nowThis phase II trial tests a new approach for recurrent nasopharyngeal carcinoma (a type of throat cancer) that has come back after initial treatment and cannot be removed by surgery. The treatment combines a special radiation schedule (low and high doses) with an immunotherapy dr…
Phase 2 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take aim at stubborn lymphoma
Disease control Recruiting nowThis early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…
Early phase 1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New stem cell collection strategy aims to reduce transplant complications
Disease control Recruiting nowThis study tests a new approach to collect stem cells for transplant in people with multiple myeloma, Hodgkin lymphoma, or non-Hodgkin lymphoma. Instead of giving everyone the drug plerixafor, doctors will start with G-CSF alone and only add plerixafor if needed. The goal is to s…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New CAR-T therapy aims to tackle tough lymphoma
Disease control Recruiting nowThis early-stage study is testing a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells…
Phase 1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New shorter chemo combo shows promise for hodgkin lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a shortened course of a drug combination called BrECADD for people with advanced Hodgkin lymphoma. The goal is to see if a shorter treatment can still control the cancer while reducing side effects. About 48 adults aged 18 to 60 will receive up to fo…
Phase 2 • Sponsor: University of Miami • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Hope for ME/CFS and long COVID: new drug combo trial launches
Disease control Recruiting nowThis study tests two drugs—pyridostigmine (Mestinon) and low-dose naltrexone (LDN)—alone or together in 160 adults with ME/CFS or Long COVID who also have orthostatic intolerance (difficulty standing). Over 3 months, participants take gradually increasing doses and complete exerc…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy aims to outsmart hodgkin lymphoma
Disease control Recruiting nowThis study tests a new way to treat advanced Hodgkin lymphoma by combining the immunotherapy drug nivolumab with chemotherapy. Doctors use PET scans early in treatment to see how well it's working and adjust therapy accordingly. The goal is to improve outcomes while reducing side…
Phase 2 • Sponsor: National Research Center for Hematology, Russia • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New cocktail of cancer drugs shows promise for tough brain tumors
Disease control Recruiting nowThis study tests a combination of three drugs—orelabrutinib, selinexor, and a chemotherapy drug—in 25 people with relapsed or refractory central nervous system lymphoma, a type of brain cancer. The goal is to see if this mix can shrink tumors better than current treatments. Parti…
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Could less radiation be enough for HPV-Positive throat cancer?
Disease control Recruiting nowThis study is testing whether a lower dose of radiation after surgery can safely treat HPV-positive head and neck cancer while reducing long-term side effects. About 304 participants will receive either standard or reduced radiation, with or without chemotherapy. The goal is to s…
Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can a blood test model flag dangerous myelosuppression before it strikes?
Diagnosis Recruiting nowResearchers are evaluating a dynamic risk prediction model for severe myelosuppression in adults with nasopharyngeal carcinoma who receive systemic anticancer treatment. The model estimates the risk of grade 3 or higher anemia, low platelets, or low white blood cells during thera…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Million-Person quest to catch a silent cancer early
Diagnosis Recruiting nowThis study aims to build a massive screening cohort of one million people to improve early detection of nasopharyngeal carcinoma, a cancer linked to Epstein-Barr virus (EBV). Participants aged 30 to 69 will provide blood, saliva, and nasal brush samples for EBV antibody and DNA t…
Sponsor: Ming-Yuan Chen • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
Can a tiny device speed up cancer diagnosis for people with HIV?
Diagnosis Recruiting nowThis study tests new diagnostic approaches for lymphoma and multicentric Castleman disease in people living with HIV who have swollen lymph nodes. Researchers will compare standard biopsies with fine needle aspiration and a new nucleic acid amplification device called TINY. The g…
Sponsor: Indiana University • Aim: Diagnosis
Last updated Aug 30, 2026 00:00 UTC
-
New blood test may sharpen diagnosis of autoimmune liver disease
Diagnosis Recruiting nowThis study evaluates whether a blood test measuring polyreactive immunoglobulin G (pIgG) can more accurately diagnose autoimmune hepatitis (AIH) and distinguish it from other liver conditions. Researchers will collect blood samples from 400 adults undergoing liver biopsy for susp…
Sponsor: Hannover Medical School • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could a special MRI spot brain lymphoma without a biopsy?
Diagnosis Recruiting nowThis trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and resea…
Phase 1 • Sponsor: James Rubenstein • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
New PET scan targets hidden cancers with precision
Diagnosis Recruiting nowThis study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…
Phase 2 • Sponsor: RenJi Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
Simple mouth swab could spot hidden throat cancer early
Diagnosis Recruiting nowThis study is testing whether a simple mouth rinse can detect HPV-related throat cancer early, before symptoms appear. Researchers will compare results from 200 people with throat cancer and 200 healthy volunteers matched by age, sex, and background. If accurate, this test could …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:03 UTC
-
New MRI scan could spot liver cancer earlier in High-Risk patients
Diagnosis Recruiting nowThis study tests whether a 20-minute MRI scan without dye can detect liver cancer earlier than the usual ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both scans every 6 months for 30 months. The goal is to see if the MRI catches cancers that…
Sponsor: University of Oxford • Aim: Diagnosis
Last updated Jun 27, 2026 07:51 UTC
-
Can pharmacy training boost HPV shots and prevent future cancers?
Prevention Recruiting nowThis study looks at whether training pharmacy staff to better communicate about and manage the HPV vaccine can increase vaccination rates in children ages 9-17. About 1,900 participants, including pharmacy staff and parents, will be involved. The goal is to make it easier for fam…
Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase 1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Could a simple education push prevent 400,000 cancers?
Prevention Recruiting nowThis trial tests whether a program called TweenVax, which provides education and training to clinics, providers, and parents, can increase HPV vaccination rates among adolescents aged 9 to 12. Researchers will compare clinics using TweenVax to those using standard vaccination pro…
Sponsor: Emory University • Aim: Prevention
Last updated Sep 05, 2026 00:00 UTC
-
Shingles sufferers: could this pill stop your pain from becoming chronic?
Prevention Recruiting nowThis study tests whether the oral medication venlafaxine, typically used for depression, can prevent postherpetic neuralgia—a persistent nerve pain that often follows a shingles rash. Researchers will enroll 832 adults who have had a shingles rash for less than 30 days and are ex…
Sponsor: Beijing Tiantan Hospital • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New transplant strategy aims to stop lymphoma from spreading to the brain
Prevention Recruiting nowThis study tests a new approach to prevent lymphoma from spreading to the brain in patients at high risk. Participants receive a stem cell transplant using drugs that better reach the brain. The goal is to see if this treatment is safe and feasible for 36 adults with newly diagno…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Aug 30, 2026 00:00 UTC
-
Shingles breakthrough? calcitonin shots aim to stop chronic pain before it starts
Prevention Recruiting nowThis phase 3 trial tests whether adding daily calcitonin injections to standard shingles treatment can prevent postherpetic neuralgia, a painful nerve condition that can last for months or years. Researchers will enroll 168 adults aged 50 and older who have had a shingles rash fo…
Phase 3 • Sponsor: Tanta University • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
Poop pills to prevent transplant rejection? new trial tests fecal transplants in blood cancer patients
Prevention Recruiting nowThis study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …
Phase 2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Shingles vaccine protection tested over 6 years in 24,740 adults
Prevention Recruiting nowThis study looks at how well a live shingles vaccine prevents shingles over 6 years in adults aged 40 and older. It follows about 24,740 people who were in an earlier vaccine trial, comparing those who got the vaccine first to those who got it later. Researchers will track new sh…
Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Shingles shot may shield seniors from heart attacks and dementia
Prevention Recruiting nowThis large study in Denmark is testing whether the shingles vaccine (Shingrix) can do more than prevent shingles—it may also lower the risk of heart attacks, strokes, and dementia. About 162,000 adults aged 65 and older will either get the vaccine or no vaccine, and researchers w…
Phase 4 • Sponsor: Tor Biering-Sørensen • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can a common antiseptic spray stop radiation burns in cancer patients?
Prevention Recruiting nowThis study tests whether a chlorhexidine spray can prevent severe skin reactions caused by radiation therapy in people with nasopharyngeal cancer. About 148 participants will use the spray or a placebo during their treatment. The goal is to see if the spray reduces the chance of …
Phase 3 • Sponsor: Jiangxi Provincial Cancer Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:26 UTC
-
Can the shingles vaccine protect those with autoimmune conditions?
Prevention Recruiting nowThis study is testing whether the shingles vaccine (RZV) works and is safe for adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus who are taking immune-suppressing drugs. Two hundred participants will receive two doses of the vaccine. Researchers will me…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
School nurses take on heart disease: 6,000 kids in prevention trial
Prevention Recruiting nowThis trial tests whether placing trained nurses in schools can prevent rheumatic heart disease in children aged 5 to 16 in Nepal and Zambia. The nurses will teach about the disease, check for strep throat, and help kids get antibiotics. The study will measure if this approach low…
Sponsor: Thomas Pilgrim • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Taurine trial targets long COVID brain fog
Symptom relief Recruiting nowThis study tests whether taking taurine supplements can reduce brain fog, memory problems, and fatigue in people with Long COVID. About 300 adults who had COVID-19 at least 3 months ago will take taurine or a placebo for 3 months. Researchers will measure changes in fatigue and t…
Phase 2/3 • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can slow breathing retrain the nervous system to fight long COVID?
Symptom relief Recruiting nowResearchers in Reunion are testing whether a slow, deep breathing technique called cardiac coherence can reduce Long COVID symptoms. The trial enrolls 200 adults diagnosed with Long COVID who live on the island. Participants practice the breathing method over six months, and rese…
Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Proton beams vs. X-Rays: can a pricier radiation spare hearts and prevent second cancers?
Symptom relief Recruiting nowResearchers are studying whether proton therapy is practical on a national scale and whether it reduces late side effects, such as second cancers and heart damage, compared with standard photon radiation. The trial enrolls adults with Hodgkin or non-Hodgkin lymphoma confined to t…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Brain training app takes on long COVID disability
Symptom relief Recruiting nowThis study tests a supervised online program called SuperCAP to see if it can improve thinking and daily functioning in people with long COVID. One hundred adults with post-COVID cognitive difficulties will either use the program or receive standard education. The goal is to redu…
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Brain retraining trial aims to ease chronic fatigue and long COVID symptoms
Symptom relief Recruiting nowThis study is testing a mind-body program called DNRS for people with ME/CFS (chronic fatigue syndrome) who may also have Long COVID. The program uses brain retraining to help calm overactive nerves and improve symptoms like fatigue, pain, and mood. Researchers will track quality…
Sponsor: University of Alberta • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New lozenge aims to ease radiation mouth sores for hours
Symptom relief Recruiting nowThis phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …
Phase 3 • Sponsor: OncoZenge AB • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
A pill to stop cancer treatment from stealing appetite?
Symptom relief Recruiting nowThis phase 3 trial tests whether megestrol acetate, a drug that stimulates appetite, can prevent weight loss in people with nasopharyngeal carcinoma undergoing chemoradiotherapy. Half of the 204 participants will take the drug daily for 11 weeks, and the other half will take a pl…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Mindfulness may offer relief for long COVID sufferers
Symptom relief Recruiting nowThis study tests whether a structured mindfulness program can reduce stress, ease Long COVID symptoms, and improve quality of life. Adults with Long COVID will be randomly assigned to start the program right away or after an 8-week wait. All participants continue their usual medi…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Fasting during chemo: a new way to ease side effects?
Symptom relief Recruiting nowThis study looks at whether fasting for 24 hours before and after chemotherapy is safe and doable for people with Hodgkin or Diffuse Large B Cell Lymphoma. 40 participants will either fast or follow standard care, tracking side effects, diet, and quality of life. The goal is to s…
Sponsor: University of Oslo • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Can magnetic pulses to the brain reverse Long-COVID smell loss, tinnitus, and fatigue?
Symptom relief Recruiting nowThis trial tests whether a type of magnetic brain stimulation, called transcranial magnetic stimulation (TMS), can improve symptoms of post-COVID syndrome, such as loss of smell, ringing in the ears, and fatigue. About 40 people who have had these symptoms for over a month after …
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Aug 21, 2026 00:00 UTC
-
Could this pill beat long COVID fatigue?
Symptom relief Recruiting nowThis phase II trial tests whether the drug sonlicromanol can reduce fatigue in 80 people with long COVID who experience post-exertional malaise (worsening symptoms after activity). Participants take the drug or a placebo twice daily for 13 weeks, and researchers measure changes i…
Phase 2 • Sponsor: Michele van Vugt • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Micro-Choices, macro impact? a novel behavioral approach takes on fatigue
Symptom relief Recruiting nowThis trial tests whether a program built around small, deliberate choices — called micro-choices — can help people with persistent fatigue, including those with long COVID. Participants attend a four-day group workshop and receive three weeks of digital support to build new habit…
Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
Can a new pill quiet the lingering fire of shingles nerve pain?
Symptom relief Recruiting nowThis trial tests whether an experimental tablet called HL-1186 can reduce the persistent nerve pain that sometimes lingers after a shingles rash heals, a condition known as postherpetic neuralgia. About 200 adults with this pain will receive either HL-1186, a placebo, or the stan…
Phase 2 • Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a precise nerve block stop shingles pain before it becomes chronic?
Symptom relief Recruiting nowThis trial compares two ultrasound-guided nerve blocks — the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block — for treating acute pain from shingles (herpes zoster) on the chest. About 90 adults with moderate to severe pain will receive …
Sponsor: Tanta University • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Could a Once-Daily pill ease nerve pain just as well as the standard Twice-Daily dose?
Symptom relief Recruiting nowThis phase 3 trial tests whether an extended-release (once-daily) form of pregabalin works as well as the standard immediate-release (twice-daily) form for relieving nerve pain caused by diabetic peripheral neuropathy or postherpetic neuralgia. About 348 adults aged 18 to 75 with…
Phase 3 • Sponsor: Brainfarma Industria Química e Farmacêutica S/A • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Heat therapy: a new hope for long COVID sufferers?
Symptom relief Recruiting nowThis study tests whether at-home lower-body heat therapy can help older adults (ages 50-90) with long COVID improve their walking ability and overall physical function. Participants will use heat therapy at home, and researchers will measure changes in walking distance, physical …
Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Magnetic pulses may clear long COVID brain fog
Symptom relief Recruiting nowThis trial tests whether a rapid, noninvasive magnetic brain stimulation called iTBS can reduce symptoms like brain fog, depression, and anxiety in people with Long COVID. Participants receive either real or sham stimulation and complete surveys, cognitive tests, and brain scans.…
Phase 2 • Sponsor: University of New Mexico • Aim: Symptom relief
Last updated Jul 17, 2026 00:00 UTC
-
Could an ALS drug clear the fog of chemo brain?
Symptom relief Recruiting nowThis study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …
Phase 2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Mouth spray could tame agonizing swallowing pain during cancer radiation
Symptom relief Recruiting nowThis clinical trial tests whether a doxepin solution spray can relieve severe breakthrough pain when swallowing, a common side effect of radiation therapy for nasopharyngeal carcinoma. About 178 patients will be randomly assigned to receive either the doxepin spray or a placebo s…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Anti-Inflammatory diet tested as long COVID fatigue fix for seniors
Symptom relief Recruiting nowThis study tests whether following a healthy US-style diet rich in anti-inflammatory foods can reduce fatigue and improve muscle and physical function in adults aged 50 and older with long COVID. Over 16 weeks, participants are randomly assigned to either receive personalized die…
Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Water workouts may clear long COVID brain fog
Symptom relief Recruiting nowThis study tests whether a program of water-based exercise followed by memory training can help Veterans with long COVID symptoms like brain fog and fatigue. About 50 people will take part over 8 months. The goal is to see if the program is safe, doable, and helpful.
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Could an antidepressant ease long COVID fatigue?
Symptom relief Recruiting nowThis study tests whether fluvoxamine, an antidepressant, can reduce severe fatigue and other symptoms in people with post-COVID. 160 adults aged 18-70 with long-lasting fatigue after COVID will receive either the drug or a placebo for 12 weeks. The goal is to see if it improves e…
Phase 3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Nerve block shot could ease Long-COVID brain fog and fatigue?
Symptom relief Recruiting nowThis study tests if a nerve block injection in the neck can reduce long-COVID symptoms like fatigue, brain fog, and heart palpitations. About 78 adults with post-COVID condition will get either the real block or a fake injection to see if it helps. The goal is to find a safe, eff…
Phase 4 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Saline solution tested as brain fog fix for long COVID and POTS patients
Symptom relief Recruiting nowThis study looks at whether a large IV bag of saline (salt water) can improve thinking problems like brain fog in people with Long COVID or a condition called POTS. About 100 adults will receive either a full or tiny dose of saline to compare effects on reaction time and memory. …
Sponsor: University of Calgary • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Zapping brain fog: new study tests tDCS for Lyme-Related memory issues
Symptom relief Recruiting nowThis study tests a new way to treat brain fog in people with post-treatment Lyme disease. Participants will play computer-based thinking games at home while receiving either real or fake brain stimulation (tDCS) for 4 weeks. Researchers will check if the active stimulation improv…
Sponsor: Columbia University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Burst of hope: new brain stimulation tackles stubborn pain
Symptom relief Recruiting nowThis study tests a new type of deep brain stimulation called 'Burst-DBS' for people with long-term facial pain or pain after a stroke. Twenty adults will have electrodes placed in the thalamus (a pain-related brain area) and try both standard and burst stimulation patterns. The g…
Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Could a tiny ear zap boost exercise recovery in chronic fatigue?
Symptom relief Recruiting nowThis study tests whether a device that gently stimulates a nerve in the ear (transcutaneous vagus nerve stimulation) can help people with chronic fatigue from fibromyalgia or long COVID get more benefit from exercise. 60 adults who still feel very tired after a standard exercise …
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New shot trio battles shingles nerve pain: exosomes, PRP, or steroids?
Symptom relief Recruiting nowThis study tests three different injections—exosomes, platelet-rich plasma (PRP), and steroids—to see which best eases long-term nerve pain after shingles. 45 adults with pain lasting at least 3 months will get four treatments every two weeks. Researchers will measure pain, quali…
Sponsor: Zagazig University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can pressurized oxygen clear long COVID brain fog?
Symptom relief Recruiting nowThis study tests whether breathing pure oxygen in a pressurized chamber (hyperbaric oxygen therapy) can improve thinking, memory, and other symptoms in people with long COVID. About 91 adults who have had cognitive problems for at least 3 months after a COVID infection will be ra…
Sponsor: Assaf-Harofeh Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New support program aims to help caregivers of frail seniors with arthritis
Symptom relief Recruiting nowThis study tests a new program called INSPIRE, designed to support informal caregivers (like family or friends) of older adults with rheumatoid arthritis and frailty. The program involves three sessions with a healthcare professional over 12 weeks, focusing on emotional support, …
Sponsor: Glostrup University Hospital, Copenhagen • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can oxygen therapy clear long COVID brain fog?
Symptom relief Recruiting nowThis study tests if hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) can ease lingering symptoms like brain fog and fatigue in people with Long COVID. Researchers will enroll 120 adults who had COVID-19 at least 3 months ago. The goal is to see if this t…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
App-Based workouts show promise for long COVID recovery
Symptom relief Recruiting nowThis study tests whether a 12-week exercise program delivered through a smartphone app can improve physical function and heart health in people with long COVID. Sixty adults with ongoing fatigue or shortness of breath after a COVID-19 infection will be randomly assigned to either…
Sponsor: University of Nove de Julho • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Could a neck injection ease long COVID fatigue and brain fog?
Symptom relief Recruiting nowThis study tests whether a single injection near a nerve cluster in the neck (stellate ganglion block) can reduce long COVID symptoms like fatigue, brain fog, and trouble breathing. About 40 adults with persistent symptoms will receive either the active injection or a placebo. Re…
Sponsor: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can a traditional chinese medicine beat long COVID fatigue?
Symptom relief Recruiting nowThis study tests whether Shengmai liquid, a traditional Chinese herbal drink, can reduce fatigue in people with Long COVID. One hundred adults aged 18-75 will take either the liquid or a placebo daily for 8 weeks. Researchers will measure changes in fatigue, mood, and sleep quali…
Phase 4 • Sponsor: Beijing University of Chinese Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Diet and exercise may ease chemo side effects for lymphoma patients
Symptom relief Recruiting nowThis study tests whether a Mediterranean diet and home-based exercise program can help lymphoma patients complete chemotherapy and reduce treatment-related side effects. Researchers will enroll 140 adults with untreated Hodgkin or non-Hodgkin lymphoma who need at least 6 cycles o…
Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New digital program aims to ease young cancer Survivors' pain and fatigue
Symptom relief Recruiting nowThis study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program uses video sessions and online materials to teach skills for managing symptoms like pain, fatigue, and emotional distress, and to encourage follow-up care. Rese…
Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Magnetic pulses to the brain may lift long COVID fog
Symptom relief Recruiting nowThis study tests a gentle brain stimulation technique called rTMS to see if it can reduce severe fatigue and concentration problems in people with long COVID. Researchers will give 66 adults either real or fake (placebo) stimulation over six weeks. The goal is to find a safe, non…
Sponsor: Amsterdam UMC, location VUmc • Aim: Symptom relief
Last updated Jun 27, 2026 08:05 UTC
-
Can acupuncture ease long COVID? tiny study aims to find out
Symptom relief Recruiting nowThis pilot study will test whether acupuncture, with or without Chinese herbal medicine, is a practical and helpful treatment for long COVID. Ten adults with long COVID will receive 16 acupuncture sessions over 8 weeks; half will also take herbal supplements. The main goal is to …
Sponsor: Southern California University of Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Cold water splash: new study tests hydrotherapy for long COVID relief
Symptom relief Recruiting nowThis study tests if cold water therapy (Kneipp hydrotherapy) can improve quality of life for people with Long COVID. Thirty adults with a Post-COVID diagnosis will either receive the cold water treatment or continue usual care. Researchers will measure changes in fatigue, sleep, …
Sponsor: Eggensberger OHG • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Veterans get fit at home: new study tests Tele-Rehab after COVID
Symptom relief Recruiting nowThis study tests whether a home-based, supervised group exercise program can help high-risk Veterans recover their fitness after COVID-19. 80 Veterans with conditions like high blood pressure or diabetes will do guided workouts from home. The goal is to improve heart and lung fun…
Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Could breathing your own air fix long COVID brain fog?
Symptom relief Recruiting nowThis study tests a device called Hi-OxSR that lets people rebreathe a small amount of their own carbon dioxide (CO2) to treat brain fog and fatigue from Long COVID. Researchers think CO2 may calm inflammation in the body. The trial will enroll 120 adults and compare different tre…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 26, 2026 16:55 UTC
-
Lyme disease mystery: do bacteria lurk after antibiotics?
Knowledge-focused Recruiting nowThis study investigates whether the bacteria causing Lyme disease can survive antibiotic treatment and cause ongoing symptoms. Researchers will follow 700 participants, including those with chronic Lyme disease, recovered individuals, and healthy volunteers, using blood tests, sp…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists seek skin samples to unlock disease secrets
Knowledge-focused Recruiting nowThis study collects biological samples—like blood, skin biopsies, and swabs—from people with or at risk for skin diseases, as well as healthy volunteers. Researchers will use these samples to study the causes of skin conditions and explore potential treatments. Up to 700 particip…
Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for hidden COVID remnants in long COVID patients
Knowledge-focused Recruiting nowThis study aims to find out whether people with long COVID still have inactive remnants of the SARS-CoV-2 virus in their bodies. Researchers will collect tissue samples from 12 adults who have recovered from COVID-19, some with long COVID symptoms and some without. The goal is to…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
HIV memory mystery: even controlled virus may harm the brain
Knowledge-focused Recruiting nowThis study looks at why some people with HIV who have very low virus levels in their blood still develop thinking and memory problems. Researchers will follow 1,150 participants—including healthy volunteers—for up to 10 years, using brain scans, blood tests, and spinal fluid samp…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists seek samples to build better Cancer-Killing drugs
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Your voice may hold clues to long COVID – researchers launch app study
Knowledge-focused Recruiting nowThis study will use the Long COVID Companion app to collect voice recordings and health questionnaires from 300 adults with ongoing COVID-19 symptoms. Researchers hope to identify vocal biomarkers for common issues like fatigue, brain fog, and breathing problems. The goal is to e…
Sponsor: Luxembourg Institute of Health • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Scientists hunt for genetic clues in Virus-Linked cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from adults with HIV, other immune disorders, or cancers thought to be caused by viruses. Researchers will compare genes in cancer tissue to normal tissue to find genetic changes that drive these cancers. The goal is to better understa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Massive liver study seeks 8,000 volunteers to unlock disease secrets
Knowledge-focused Recruiting nowThis study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
NIH launches major study to unravel mysteries of long COVID recovery
Knowledge-focused Recruiting nowThis study follows 1,590 adults who have had COVID-19 to track their symptoms and recovery over three years. Participants complete phone interviews and online surveys every three months. The goal is to describe the range of recovery experiences and identify factors that lead to p…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Scientists collect samples to unlock secrets of lymphoid cancers
Knowledge-focused Recruiting nowThis study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Study aims to uncover hidden delays in anal cancer diagnosis
Knowledge-focused Recruiting nowThis study looks at the care paths of 300 people with anal cancer to find out what causes delays in diagnosis. Researchers will track the time from first symptoms to diagnosis and check how screening and access to care affect outcomes. The goal is to improve awareness and help ca…
Sponsor: Centre Hospitalier Intercommunal Creteil • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Survivors' hidden toll: chest radiation linked to brain changes
Knowledge-focused Recruiting nowThis study looks at Hodgkin lymphoma survivors who had chest radiation and bleomycin treatment as children. Researchers want to understand how these treatments affect blood flow to the brain and heart-lung function during exercise. About 100 survivors and healthy volunteers will …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Scientists launch Decade-Long watch on kaposi sarcoma
Knowledge-focused Recruiting nowThis study follows 150 adults with Kaposi sarcoma (KS) for up to 10 years to learn how the disease behaves, why it comes back, and how it affects the immune system and organs. Participants will have regular check-ups, scans, and biopsies, but no new treatments are being tested. T…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Which germs drive a severe ear infection? a new study aims to find out
Knowledge-focused Recruiting nowThis study will collect ear swabs from 40 people with malignant otitis externa, a severe infection of the ear canal that mainly affects people with diabetes or weakened immune systems. Researchers will culture the samples to identify the bacteria and fungi causing the infection a…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Small study aims to personalize drug dosing for young cancer patients
Knowledge-focused Recruiting nowThis study looks at how young people (ages 6-25) with Hodgkin or non-Hodgkin lymphoma process certain medications. Researchers will give tiny, non-therapeutic doses of two common drugs (omeprazole and dextromethorphan) and measure how they are broken down in the body. The goal is…
Phase 1 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Could new scans revolutionize nasopharyngeal cancer care?
Knowledge-focused Recruiting nowThis observational study will test whether two new types of PET/CT scans can more accurately stage nasopharyngeal carcinoma and predict how well patients respond to immunotherapy before treatment. About 732 participants aged 18-70 with newly diagnosed, untreated cancer will recei…
Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
Can a simple blood test predict heart trouble in childhood cancer survivors?
Knowledge-focused Recruiting nowThis study looks at how certain blood cell changes (called clonal hematopoiesis) after Hodgkin lymphoma treatment might be linked to later heart problems. Researchers will test blood samples from 190 survivors who received chemotherapy as children or young adults. The goal is to …
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Researchers launch long-term observation study for rare KSHV-linked disease
Knowledge-focused Recruiting nowThis study follows 195 adults with KSHV-associated multicentric Castleman's disease (MCD) to better understand how the disease progresses and responds to treatments. Participants receive standard care and regular check-ups over several years. The goal is to improve future treatme…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can saliva reveal the secrets of long COVID?
Knowledge-focused Recruiting nowThis study aims to understand why some people develop Long COVID—persistent symptoms after a COVID-19 infection—by tracking symptoms over time and analyzing saliva samples. Researchers will follow 500 adults aged 18 to 75 who have previously tested positive for SARS-CoV-2, collec…
Sponsor: University of North Carolina, Chapel Hill • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Digital fatigue detectives: can wearables unmask the hidden toll of MS and long COVID?
Knowledge-focused Recruiting nowThis study explores whether smartphone apps and wearable devices can objectively measure fatigue in people with multiple sclerosis (MS) and long COVID, compared to healthy volunteers. Fatigue is often reported through subjective questionnaires, which can be biased. Participants w…
Sponsor: Liliana Barrios • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Massive study aims to crack the code on Kids' medications
Knowledge-focused Recruiting nowThis study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Scientists dig into past cases of rare lymphoma to find clues for better care
Knowledge-focused Recruiting nowThis study will review the medical records of 200 people diagnosed with plasmablastic lymphoma, a rare blood cancer, between 2000 and 2022. Researchers want to learn more about the disease's features, treatments used, and what affects survival. No new treatments are given; the go…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can glucocorticoid treatment skew bone health tests? a study investigates
Knowledge-focused Recruiting nowThis study follows 160 people with inflammatory joint disease who are starting treatment with or without glucocorticoids, or receiving a glucocorticoid injection. Researchers will measure bone turnover markers (P1NP and CTX1) in blood samples every 4 weeks and up to 6 months afte…
Sponsor: Diakonhjemmet Hospital • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Hunting for biological clues to long COVID's mysteries
Knowledge-focused Recruiting nowThis study aims to uncover the biological changes behind Long COVID and identify laboratory tests, or biomarkers, that could help diagnose the condition and measure its progression. Researchers will enroll 150 adults—some with Long COVID and others who fully recovered from COVID-…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
New brain scans may uncover hidden HIV damage
Knowledge-focused Recruiting nowThis study uses special PET scans to measure brain synapse density in people with HIV who are on effective treatment. Researchers want to understand why some still develop thinking or memory problems. They will compare 70 participants (with and without HIV) over two years using b…
Phase 1/2 • Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
Can tracking thousands of patients unlock the secrets of rare EBV-driven blood cancers?
Knowledge-focused Recruiting nowThis study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…
Sponsor: Rong Tao • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Massive blood cancer registry aims to unlock secrets of adult ALL
Knowledge-focused Recruiting nowThis study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…
Sponsor: Goethe University • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
What happens years after CAR-T therapy? a study aims to find out
Knowledge-focused Recruiting nowThis study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…
Sponsor: Miltenyi Biomedicine GmbH • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Dietary change explored as cancer support strategy
Knowledge-focused Recruiting nowThis early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…
Early phase 1 • Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
500 patients to be tracked for long-term safety of cancer cell therapy
Knowledge-focused Recruiting nowThis study follows 500 people in South Korea who have received tisagenlecleucel, a CAR-T cell therapy, for certain blood cancers like acute lymphoblastic leukemia and lymphomas. Researchers will monitor side effects, risk of new cancers, and how well the treatment works over time…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Can a simple blood test unlock the secrets of brain autoimmune diseases?
Knowledge-focused Recruiting nowThis study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
What happens to the immune system after COVID-19? a major study aims to find out.
Knowledge-focused Recruiting nowThis study follows 800 adults who have recovered from COVID-19 to understand how their immune systems respond over the long term. By collecting blood samples and health data, researchers hope to uncover why some people develop lingering symptoms, known as Long COVID. The goal is …
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New study aims to boost cervical cancer care for HIV-Positive women in mozambique
Knowledge-focused Recruiting nowThis study will test a new way to screen and treat cervical cancer in women with HIV in Mozambique. About 8,445 women aged 25-49 who are already receiving HIV care will be offered HPV testing and same-day treatment if needed. The goal is to see if this approach can screen more wo…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
New 3D scanner could revolutionize how doctors measure kaposi sarcoma
Knowledge-focused Recruiting nowThis study will test a new 3D imaging device called SkinScan3D to see if it can measure Kaposi Sarcoma skin lesions more accurately and consistently than the current manual method. Researchers will compare the two methods in 300 adults with confirmed Kaposi Sarcoma who are starti…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Bergamo hospitals launch hunt for hidden hepatitis delta cases
Knowledge-focused Recruiting nowThis study aims to find out how many people with hepatitis B also have hepatitis delta, a more serious liver infection. Researchers will test 244 adults in hospitals, addiction clinics, and prisons in Bergamo, Italy. The goal is to improve detection and understand the true burden…
Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Exercise may turn back the clock for blood cancer survivors
Knowledge-focused Recruiting nowThis study looks at whether a tailored exercise program can help older blood cancer survivors slow down the aging process. Researchers will enroll 180 people aged 50 and older who have had blood cancer. The goal is to see if participants can stick with the exercise plan and if it…
Sponsor: University of Nebraska • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood test may spot hidden sarcoma signals
Knowledge-focused Recruiting nowThis study investigates whether fragments of tumor DNA circulating in the blood can be used to detect and monitor soft tissue sarcoma. Researchers will collect blood and tumor tissue samples from 40 adults with high-risk sarcomas to see if this DNA can serve as a biomarker for ca…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Hidden threat: hepatitis d prevalence under the microscope
Knowledge-focused Recruiting nowThis study aims to find out how often people with chronic hepatitis B also have hepatitis D, and which types of the virus are most common. Researchers will interview about 2,400 participants and take blood samples to look for links with vaccination history, lifestyle, and other f…
Sponsor: Tam Anh Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Long-Term heart risks after rare COVID complication in kids under scrutiny
Knowledge-focused Recruiting nowThis study looks at heart health in children five years after they had MIS-C, a rare but serious condition linked to COVID-19. Researchers will compare 90 children who had MIS-C with healthy children of the same age and sex. They will use heart imaging, blood vessel checks, exerc…
Sponsor: Medical University of Warsaw • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists hunt for long COVID fingerprints in the brain and blood
Knowledge-focused Recruiting nowThis study looks for specific signs of long COVID in the brain and blood. Researchers will compare people with and without long COVID symptoms using brain scans and blood tests. The goal is to find objective markers that could help doctors diagnose long COVID more reliably.
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood cancer patients' journeys mapped over a decade
Knowledge-focused Recruiting nowThis study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Austrian study seeks to eliminate hepatitis by linking patients to care
Knowledge-focused Recruiting nowThis study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…
Sponsor: Vanessa Stadlbauer-Koellner, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lyme disease and parenthood: a hidden struggle revealed
Knowledge-focused Recruiting nowThis study explores the real-life experiences of people who had Lyme disease during or before pregnancy and are now raising children. Participants fill out surveys about their health, mental well-being, and child development, then take part in an interview to share their personal…
Sponsor: Children's National Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lyme disease in pregnancy: new study tracks baby brain development
Knowledge-focused Recruiting nowThis study follows 40 pregnant women with Lyme disease to see how the infection might affect their baby's development. Researchers will monitor pregnancies and check infant growth, thinking, and motor skills from birth to 18 months. The goal is to learn if Lyme exposure in the wo…
Sponsor: Children's National Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Lupus Patients' shingles vaccine response under the microscope
Knowledge-focused Recruiting nowThis study looks at how well the shingles vaccine (Shingrix) works in people with lupus compared to healthy people of the same age and sex. Researchers will measure immune cell responses after two doses and follow participants for up to 5 years. The goal is to understand if the v…
Sponsor: Seoul National University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Mapping the immune System's fight against certain cancers
Knowledge-focused Recruiting nowThis study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Crushed cancer pill study aims to help kids who Can't swallow tablets
Knowledge-focused Recruiting nowThis study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
New risk model may personalize Post-Chemo decisions for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis observational study is testing whether a new tool called RAIRI can better identify which patients with nasopharyngeal cancer might benefit from additional therapy after standard chemoradiation. About 900 adults with non-metastatic disease will be followed to see if the RAIRI…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Scientists seek tissue samples to unlock HIV-Cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…
Sponsor: AIDS Malignancy Consortium • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
New study hopes to predict hodgkin lymphoma outcomes better
Knowledge-focused Recruiting nowThis observational study is looking for better ways to predict how Hodgkin lymphoma will progress. Researchers will analyze genetic material from tumor samples and blood tests, along with PET scan images, from 755 patients. The goal is to identify markers that could help doctors …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New database aims to crack the code on three rare skin cancers
Knowledge-focused Recruiting nowThis study is building a large French database of patients with three rare skin cancers: Merkel cell carcinoma, advanced basal cell carcinoma, and cutaneous adnexal carcinomas. Researchers will track up to 9,000 participants to learn how these cancers behave, what factors affect …
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Why do some teens stay fatigued after mono? new study aims to find out
Knowledge-focused Recruiting nowThis study looks at why some teenagers and young adults feel tired for months after getting Epstein-Barr virus (the virus that causes mono). Researchers will follow 150 infected people and 150 healthy people for six months, using brain scans, immune tests, and questionnaires. The…
Sponsor: University Hospital, Akershus • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists hunt for clues in COVID Patients' blood and secretions
Knowledge-focused Recruiting nowThis study collects blood and nasal secretions from up to 2,000 people with COVID-19 to learn why some get very sick while others recover easily. Researchers will also track long-term symptoms like fatigue and brain fog. No treatments are tested—the goal is to gather data to guid…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive global registry aims to predict heart damage from cancer therapy
Knowledge-focused Recruiting nowThis study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can a simple test predict who will beat advanced nose cancer?
Knowledge-focused Recruiting nowThis study looks at 50 people with nasopharyngeal cancer that has come back or spread. Researchers will use advanced lab tests (multi-omics) to see if they can predict how well a combination of chemotherapy, radiation, and immunotherapy works. The goal is to find better ways to p…
Sponsor: Sun Yat-sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Mayo clinic launches study to uncover long COVID lung mysteries
Knowledge-focused Recruiting nowThis study aims to understand why some people continue to have symptoms like shortness of breath and fatigue long after a severe COVID-19 infection. Researchers will follow 67 adults for up to 12 months, using scans, blood tests, and other measures to look for clues in the lungs …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Cancer immunotherapy may weaken bones, new study warns
Knowledge-focused Recruiting nowThis study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…
Sponsor: Jessica Mezzanotte Sharpe • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
5,000 patients worldwide to help perfect cancer staging system
Knowledge-focused Recruiting nowThis international study aims to improve how doctors stage nasopharyngeal cancer by collecting data from 5,000 patients across multiple countries. Researchers will use this information to refine the TNM staging system and combine it with other factors like biomarkers. The goal is…
Sponsor: The University of Hong Kong-Shenzhen Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Mystery illness after COVID shot? new study seeks answers
Knowledge-focused Recruiting nowThis study looks at people who have long-lasting health problems after getting the COVID-19 vaccine, a condition called Post-Acute COVID-19 Vaccination Syndrome (PACVS). Researchers will track symptoms over eight months and test blood and blood vessel function to find biological …
Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Rare ovarian cancer under the microscope: new study seeks answers
Knowledge-focused Recruiting nowThis study is collecting information from 30 patients with an extremely rare ovarian cancer called primary ovarian leiomyosarcoma. Researchers will look at past and new cases to find patterns in how the cancer is diagnosed and treated. The goal is to create better guidelines for …
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Blood test could predict brain inflammation relapses in kids
Knowledge-focused Recruiting nowThis study aims to find blood-based biomarkers that can predict whether a child with acute disseminated encephalomyelitis (ADEM) will experience relapses. Researchers will analyze immune cells from blood samples of 20 children aged 1-18 with a first demyelinating event. The goal …
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
CAR T-Cell survivors: what happens years later?
Knowledge-focused Recruiting nowThis study follows 80 children and young adults who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL) at least two years ago. Researchers want to see how feasible it is to track their long-term health, including any new or lasting side effects, brain fun…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Scientists hunt for lymphoma genes in families with multiple cases
Knowledge-focused Recruiting nowThis study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists probe cell energy in long COVID mystery
Knowledge-focused Recruiting nowThis study looks at how the body's cells use oxygen in people with long COVID compared to those fully recovered. Researchers will measure oxygen use in blood cells, skin, and muscle to see if there are differences. The goal is to better understand long COVID and test if these mea…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Hunting for hidden genetic triggers of severe childhood epilepsy
Knowledge-focused Recruiting nowThis study aims to find genetic mutations in the brain that cause drug-resistant epilepsy in children. Researchers will compare DNA from blood and brain tissue, including samples from special electrodes placed in the brain. The goal is to better understand the root causes of thes…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New study tracks hidden organ damage after COVID-19
Knowledge-focused Recruiting nowThis study follows 650 adults in Quebec to learn about the short- and long-term health problems caused by COVID-19, including damage to the heart, lungs, kidneys, and other organs. Participants include people who had mild, moderate, or severe COVID-19, as well as those who never …
Sponsor: Emilia Falcone, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut bacteria clues sought for Post-Infection IBS
Knowledge-focused Recruiting nowThis observational study is looking at the gut microbiome of 315 people, including those with irritable bowel syndrome that started after an infection. Researchers will compare their gut bacteria to people who had an infection but no IBS, and to healthy controls. The goal is to f…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Massive european study launches to unlock secrets of rare head and neck cancers
Knowledge-focused Recruiting nowThis large observational registry aims to collect data from over 13,000 adults across Europe with rare head and neck cancers, including cancers of the nasopharynx, nasal cavity, salivary glands, and middle ear. Researchers will track patient outcomes like survival, treatment resp…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Veterans' brain fog after COVID: new study seeks answers
Knowledge-focused Recruiting nowThis study looks at why some veterans experience ongoing brain fog and other mental health issues after COVID-19. Researchers will track 200 veterans over time, using memory tests and blood samples to find clues. The goal is to better understand these symptoms and identify target…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New tool aims to predict cancer treatment toxicity in older patients
Knowledge-focused Recruiting nowThis study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a ver…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New 3D camera could revolutionize how we track kaposi sarcoma
Knowledge-focused Recruiting nowThis study tests a new 3D imaging device called SkinScan3D to see if it can take better pictures of Kaposi sarcoma (KS) skin lesions than standard 2D photos. KS lesions can change in height when they respond to treatment, which 2D photos miss. The study will enroll 30 adults with…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Hunting for hidden antibodies in brain inflammation
Knowledge-focused Recruiting nowThis study aims to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. Researchers will analyze blood and spinal fluid from 20 patients to find new antibodies that may explain the disease in people who currently test negative. The goa…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Chemo brain hits blood cancer patients too – new study investigates
Knowledge-focused Recruiting nowThis study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…
Sponsor: University Hospital, Angers • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study aims to tailor hodgkin lymphoma care for african children without radiation
Knowledge-focused Recruiting nowThis study follows 250 children under 18 with Hodgkin lymphoma in Africa. Researchers want to see if simple, standardized treatment plans can work even when radiation therapy is not available. The goal is to improve access to effective care by adapting guidelines to local resourc…
Sponsor: French Africa Pediatric Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Leukemia treatment may erase vaccine protection—study tests if re-vaccination works
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) treated for B-cell acute lymphoblastic leukemia with the immunotherapy drug blinatumomab still have protection from routine childhood vaccines. Researchers will measure antibody levels for diseases like tetanus,…
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
800-Patient study aims to tailor sarcoma treatment
Knowledge-focused Recruiting nowThis study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is …
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Gut check: new study probes how hepatitis drug changes your microbiome
Knowledge-focused Recruiting nowThis study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New registry aims to unravel mysteries of long COVID
Knowledge-focused Recruiting nowThis observational study will enroll 200 people in Navarre who have had COVID-19 and still have symptoms lasting more than 3 months. Researchers will collect information on demographics, health history, and ongoing symptoms to better understand long COVID. The goal is to describe…
Sponsor: Fundacion Miguel Servet • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
800 patients to help scientists grow liver tumors in the lab
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
New study scans brains to uncover why COVID-19 triggers depression
Knowledge-focused Recruiting nowThis study uses PET and MRI scans to look at brain changes in people who developed depression within three months after a mild or moderate COVID-19 infection. Researchers will compare brain scans of 90 participants to see if key brain chemicals are altered. The goal is to better …
Sponsor: Centre for Addiction and Mental Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Can a simple blood or joint fluid test predict knee arthritis outcomes?
Knowledge-focused Recruiting nowThis study will follow 300 people with knee osteoarthritis or chronic inflammatory arthritis for up to 10 years. Researchers will collect blood, joint fluid, and platelet-rich plasma samples to look for biomarkers linked to pain, joint damage, and the need for knee replacement. T…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Veterans study: does poor sleep worsen long COVID brain fog?
Knowledge-focused Recruiting nowThis study looks at how sleep issues and sleep apnea might affect thinking, memory, and daily life in people who had COVID-19. Researchers will follow 200 veterans for up to a year, testing their brain function, sleep quality, and exercise ability. The goal is to find out if trea…
Sponsor: VA Office of Research and Development • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Long-COVID mystery: new study aims to decode patient subtypes
Knowledge-focused Recruiting nowThis study looks at 150 adults with long-COVID to group them by their symptoms and link those groups to lab results. The goal is to find patterns that could help doctors predict outcomes and discover new treatments. Participants will have their health data and blood samples analy…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Housebound no more: new study brings doctors to the bedside of ME/CFS patients
Knowledge-focused Recruiting nowThis study focuses on people with ME/CFS or Long COVID who are too sick to leave home. Researchers will provide monthly in-home medical visits and create personalized care plans. The goal is to see if this approach improves patients' health and eases the burden on their caregiver…
Sponsor: Hannover Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Blood test may outsmart PET scans in childhood cancer
Knowledge-focused Recruiting nowThis study is testing whether a simple blood test (called a liquid biopsy) can better predict relapse in children and young adults with classical Hodgkin lymphoma. Researchers will track 400 patients under 25 to see if tumor DNA in the blood can catch early signs of relapse or tr…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
Scientists track immune cells in hepatitis d patients on new drug
Knowledge-focused Recruiting nowThis study looks at how the immune system fights hepatitis D in people who also have hepatitis B. Researchers will measure special immune cells (T cells) in 192 adults before and after 12 months of treatment with the drug bulevirtide. The goal is to see if these immune responses …
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
AI takes on mysterious uterine tumors: a new hope for accurate diagnosis
Knowledge-focused Recruiting nowThis study is testing whether artificial intelligence can help doctors better classify and predict the behavior of rare smooth muscle tumors of the uterus, including those that are hard to diagnose (called STUMP). Researchers will train AI models on digital images of tumor tissue…
Sponsor: Institut Bergonié • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New rapid test could transform hepatitis b and d management
Knowledge-focused Recruiting nowThis observational study aims to develop a rapid T-cell test to help manage patients with chronic hepatitis B (HBV) and hepatitis B/D (HBV/HDV) co-infection. Researchers will analyze immune responses in 300 adult patients to understand how T-cells react to the viruses. The goal i…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Heart MRI breakthrough could spot hidden risks in thousands
Knowledge-focused Recruiting nowThis study is testing whether a detailed heart MRI (called T1 mapping) can better predict who will develop heart disease, heart failure, or long COVID complications. Researchers will scan 6000 adults without known heart disease and follow them over time. The goal is to see if sub…
Sponsor: Johann Wolfgang Goethe University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists hunt for clues to tell apart two Look-Alike lymphomas
Knowledge-focused Recruiting nowThis study looks at rare lymphomas that are hard to tell apart under the microscope—some look like Hodgkin lymphoma but lack a key marker (PAX5), making them similar to another type called anaplastic large cell lymphoma (ALCL). Researchers will analyze tissue samples from 60 adul…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Shingles may trigger dementia: study probes hidden danger
Knowledge-focused Recruiting nowThis observational study looks at whether people with shingles (herpes zoster) have a higher risk of vascular dementia—memory loss from reduced blood flow to the brain. Researchers will analyze tiny particles called exosomes in blood samples from 375 participants over 12 months. …
Sponsor: Center for Clinical Studies, Texas • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New registry aims to uncover how aging affects blood cancer patients
Knowledge-focused Recruiting nowThis study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New study aims to catch lung disease early in arthritis patients
Knowledge-focused Recruiting nowThis study will observe 800 adults with rheumatoid arthritis in Austria to create a standard screening method for lung complications. Researchers will use CT scans, lung function tests, and AI analysis to identify those at high risk. The goal is to detect lung problems earlier an…
Sponsor: Medical University Innsbruck • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New study seeks biomarkers to personalize radiation for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis study enrolls 500 adults with nasopharyngeal carcinoma (stage I-III) who are receiving chemoradiotherapy with either proton or photon radiation. Researchers will collect imaging scans and blood samples to find markers that predict how well the cancer responds, side effects, …
Sponsor: Cheng-En Hsieh • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Scientists test immune cells against rare skin cancer in the lab
Knowledge-focused Recruiting nowThis study is testing a new cell therapy in the lab for people with Merkel cell carcinoma, a rare skin cancer linked to a virus. Researchers will take immune cells from 15 patients and try to train them to attack the cancer in a test tube. The goal is to see if this approach work…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Blood test may spare throat cancer patients from radiation side effects
Knowledge-focused Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove their tumor. Researchers are testing whether a blood test that looks for leftover tumor DNA can safely identify patients who do not need additional radiation. The goal is to reduce side effects by …
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
CAR-T cell patients monitored for 15 years in new study
Knowledge-focused Recruiting nowThis study follows 500 people who received CAR-T cells in earlier trials for blood cancers like lymphoma and multiple myeloma. Researchers will check for new cancers and track long-term safety and effectiveness over 15 years. No new treatment is given; it is purely an observation…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
New scan could help doctors pick the right treatment for nasopharyngeal cancer
Knowledge-focused Recruiting nowThis study tests whether a special PET scan can show how much of a certain protein (SSTR2) is present in nasopharyngeal cancer tumors. Ten adults with EBV-related nasopharyngeal cancer will get the scan before and after starting chemotherapy or chemoradiation. The goal is to see …
Phase 1/2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Could a weekend of brain zaps ease depression and long COVID?
Knowledge-focused Recruiting nowThis pilot study tests whether an intensified schedule of repetitive transcranial magnetic stimulation (iTBS) — six sessions a day for five days — works better than the standard one-session-a-day for six weeks in people with depression and Post-COVID condition. Researchers will m…
Sponsor: Max-Planck-Institute of Psychiatry • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Can a simple test predict who will beat skin cancer with immunotherapy?
Knowledge-focused Recruiting nowThis study is testing a new predictive model that analyzes tumor samples to forecast whether a patient with melanoma or other skin cancers will respond to immunotherapy. Researchers will compare the model's predictions with actual patient outcomes over six months. The goal is to …
Sponsor: Melanoma Institute Australia • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC